Canadian biopharma companies are capitalizing on increased government investment stimulated by the recent pandemic to strengthen domestic capabilities and foster multinational partnerships that enhance drug discovery and development worldwide.

With obesity medicines now household names, the race is on amongst the pioneers and competitor companies to bring improved products to market.

Broad-reaching modalities such as ADCs, bi-specifics and radiopharmaceuticals were popular in 2024 and are likely to remain hot this year.

The need to get novel biologic modalities to the right place effectively and efficiently is highlighted in major recent deals around drug delivery platforms.

In conversation with Eric Esser, President and Chief Executive Officer, Telesis Bio

The clinical success of biologics is often hindered by a lack of safe, targeted delivery systems. SiVEC Biotechnologies aims to change this with its groundbreaking BactPac platform.

By detecting and targeting myeloid-dependent immune suppression, Bectas Therapeutics is on a mission to realize the full potential of cancer immunotherapies.

Bio-Sourcing is developing innovative solutions that combine cutting-edge gene-editing and nuclear-transfer technologies to up-scale the production of biopharmaceuticals while lowering carbon emissions and costs.

PROVIREX is developing first-in-class advanced therapies that may offer the chance of a cure for people with life-threatening persistent viral infections.

Aleta Biotherapeutics is using its novel technology platform to develop bespoke, multi-antigen-targeting biologics for a diverse range of indications, including B-cell cancers and solid tumors, improving outcomes in patient populations with high unmet need.

Current guidelines recommend transdermal delivery of testosterone for post-menopausal women seeking treatment for hypoactive sexual desire disorder. Medherant’s TEPI patch has been developed to fill this unmet medical need.

Transcenta is employing its unique, cutting-edge discovery technology to develop antibody-based therapies that address unmet medical needs in oncology, immunology and inflammation.

With its innovative VECTrans platform, Vect-Horus is enabling targeted drug delivery across the blood–brain barrier, potentially transforming the treatment of neurodegenerative disorders.